Anthem Biosciences Limited has issued corporate guarantees totaling ₹49.00 crores to facilitate working capital credit facilities for its wholly owned subsidiary, Neoanthem Lifesciences Private Limited. The company informed stock exchanges about this development on January 07, 2026, under Regulation 30 of SEBI LODR Regulations.

Guarantee Structure and Banking Partners

The corporate guarantees have been structured across two major banking institutions to support Neoanthem's operational funding requirements:

These guarantees serve as security for various fund-based working capital credit facilities sanctioned by the respective lenders for Neoanthem Lifesciences Private Limited.

Transaction Details and Terms

The corporate guarantee arrangement includes several key operational parameters. The funds from these credit facilities will be exclusively utilized for meeting the working capital requirements of Neoanthem. The guarantees will remain in force until the full and final payment of all obligations to the lenders' satisfaction.

Anthem Biosciences has confirmed that promoters, promoter groups, and group companies have no direct interest in this transaction, and the corporate guarantee has been issued on an arm's length basis.

Financial Impact Assessment

The company has provided a clear assessment of the financial implications of these guarantees:

Regulatory Compliance

Anthem Biosciences has fulfilled its disclosure obligations by informing both major stock exchanges about this corporate guarantee issuance. The company submitted the required intimation to BSE Limited and National Stock Exchange of India Limited, providing comprehensive details as mandated under SEBI regulations.

The disclosure includes all necessary information as per Regulation 30 of SEBI LODR Regulations and SEBI Master Circular dated November 11, 2024. Complete details of the transaction have also been made available on the company's official website for investor access.

Anthem Biosciences Limited , a prominent player in the biosciences sector, has reported violations of its insider trading code by two designated persons, according to a recent disclosure to stock exchanges.

Details of the Violations

The company revealed that two of its employees, Srinivas L and Bhuvaneswari M, breached the company's Code of Conduct to Regulate, Monitor and Report Trading by Designated Persons. Here are the key details of the violations:

Srinivas L's Case

Srinivas L sold an aggregate of 674 equity shares on two separate occasions during the trading window closure period, which began on October 1, 2025. These shares were originally allotted to him under the Company's ESOP Scheme. The transactions occurred despite explicit instructions to the pledgee not to sell the pledged shares during the restricted period.

Bhuvaneswari M's Case

Bhuvaneswari M sold 5,000 equity shares amounting to Rs. 41,75,000 on September 15, 2025, without obtaining the required pre-clearance approval. She had previously obtained approval on August 25, 2025, which was valid until August 31, 2025. Due to a medical emergency and subsequent leave, she missed the validity period and executed the transaction without renewed approval.

Company's Response

Anthem Biosciences has taken these breaches seriously. The Audit Committee, in its meeting held on November 6, 2025, resolved to:

1. Issue warning letters to both designated persons, instructing them to ensure strict adherence to the Code and regulatory requirements going forward.
2. Obtain acknowledgment letters from the individuals confirming their commitment to strictly adhere to the Company's Code of Conduct in the future.

The company has emphasized that any future violations will attract stricter disciplinary action.

Regulatory Compliance

The company has reported these violations as per the requirements of Schedule B read with Regulation 9(1) of SEBI (Prohibition of Insider Trading) Regulations, 2015. This disclosure demonstrates Anthem Biosciences' commitment to transparency and regulatory compliance in matters of insider trading.

These incidents underscore the importance of strict adherence to insider trading regulations and the need for continuous education and vigilance among designated persons in listed companies.